Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 42, 2012 - Issue 3
366
Views
5
CrossRef citations to date
0
Altmetric
General Xenobiochemistry

Microbial production of phase I and phase II metabolites of midazolam

, , , &
Pages 285-293 | Received 23 Jul 2011, Accepted 07 Sep 2011, Published online: 24 Oct 2011

References

  • Bjornsson TD. et al. (2003). The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443–469.
  • Christensen H, Mathiesen L, Postvoll LW, Winther B, Molden E. (2009). Different enzyme kinetics of midazolam in recombinant CYP3A4 microsomes from human and insect sources. Drug Metab Pharmacokinet 24:261–268.
  • Dundee JW, Halliday NJ, Harper KW, Brogden RN. (1984). Midazolam. A review of its pharmacological properties and therapeutic use. Drugs 28:519–543.
  • Emoto C, Iwasaki K. (2007). Relative roles of CYP2C19 and CYP3A4/5 in midazolam 1′-hydroxylation. Xenobiotica 37:592–603.
  • Emoto C, Murase S, Sawada Y, Iwasaki K. (2005). In vitro inhibitory effect of 1-aminobenzotriazole on drug oxidations in human liver microsomes: a comparison with SKF-525A. Drug Metab Pharmacokinet 20:351–357.
  • Engstrom KM, Daanen JF, Wagaw S, Stewart AO. (2006). Gram scale synthesis of the glucuronide metabolite of ABT-724. J Org Chem 71:8378–8383.
  • Fischer B, Nudelman A, Ruse M, Herzig J, Gottlieb HE, Keinan E. (1984). A Novel Method for Stereoselective Glucuronidation. J Org Chem 49:4988–4993.
  • Grogan GJ, Holland HL. (2000). The biocatalytic reactions of Beauveria spp. J Mol Cat B Enzym 9:1–32.
  • Heizmann P, Eckert M, Ziegler WH. (1983). Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 16 Suppl 1:43S–49S.
  • Heizmann P, Ziegler WH. (1981). Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittelforschung 31:2220–2223.
  • Hyland R, Osborne T, Payne A, Kempshall S, Logan YR, Ezzeddine K, Jones B. (2009). In vitro and in vivo glucuronidation of midazolam in humans. Br J Clin Pharmacol 67:445–454.
  • Jian Z, Wu A, Lin M, Lawrence J, Ray T. (2010). Synthetic studies of [M+5] hydroxymidazolam. J Label Compd Radiopharm. Special issues: 10th international symposium on the synthesis and applications of isotopes and isotopically labelled compounds—synthesis of compounds labelled with long-lived isotopes, June 2009, 53:239–268.
  • Klieber S, Hugla S, Ngo R, Arabeyre-Fabre C, Meunier V, Sadoun F, Fedeli O, Rival M, Bourrie M, Guillou F, Maurel P, Fabre G. (2008). Contribution of the N-glucuronidation pathway to the overall in vitro metabolic clearance of midazolam in humans. Drug Metab Dispos 36:851–862.
  • Maekawa K, Yoshimura T, Saito Y, Fujimura Y, Aohara F, Emoto C, Iwasaki K, Hanioka N, Narimatsu S, Niwa T, Sawada J. (2009). Functional characterization of CYP3A4.16: catalytic activities toward midazolam and carbamazepine. Xenobiotica 39:140–147.
  • Marvalin C, Azerad R. (2011a). Microbial glucuronidation of polyphenols. J Mol Catal B: Enzym. (In Press). Doi:10.1016/j.molcatb.2011.07.015.
  • Marvalin C, Azerad R. (2011b). Microbial production of phase I and phase II metabolites of propranolol. Xenobiotica 41:175–186.
  • Muchohi SN, Ward SA, Preston L, Newton CR, Edwards G, Kokwaro GO. (2005). Determination of midazolam and its major metabolite 1′-hydroxymidazolam by high-performance liquid chromatography-electrospray mass spectrometry in plasma from children. J Chromatogr B Analyt Technol Biomed Life Sci 821:1–7.
  • Nicoli R, Bartolini M, Rudaz S, Andrisano V, Veuthey JL. (2008). Development of immobilized enzyme reactors based on human recombinant cytochrome P450 enzymes for phase I drug metabolism studies. J Chromatogr A 1206:2–10.
  • Rogers JF, Rocci ML Jr, Haughey DB, Bertino JSJr.(2003). An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin Pharmacol Ther 73:153–158.
  • Roy SN, Denoux M, Brasseur D, Philippe N, De Bruin B, Perard S, Allen J. (2007). The use of biocatalysis in the synthesis of labelled compounds. J Label Compd Radiopharm 50:342–346.
  • Scheinmann F, Lumbard KW, Brown RT, Mayalarp SP, Carter NE. (1993). A process for making morphine-6-glucuronide or substituted morphine-6-glucuronide. 18.02.1993, WO 93/03051.
  • Seo KA, Bae SK, Choi YK, Choi CS, Liu KH, Shin JG. (2010). Metabolism of 1′- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7. Drug Metab Dispos 38:2007–2013.
  • Siddle DW, Faithfull L, Gleave M, Wright P, Lindsay N, Kohl C. (2003). Midazolam is metabolised by UGT1A4 in human hepatocytes and hepatic microsomes. Drug Metabol Rev, 35 (Suppl 1):55.
  • Streetman DS, Bertino JS Jr, Nafziger AN. (2000). Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10:187–216.
  • Walser A, Benjamin LE, Flynn T, Mason C, Schwartz R, Fryer RI. (1978). Quinazolines and 1,4-benzodiazepien. 84. Synthesis and reactions of imidazo[1,5-a][1,4]benzodiazepines. J Org Chem 43:936–944.
  • Zhang Y, Griendling KK, Dikalova A, Owens GK, Taylor WR. (2005). Vascular hypertrophy in angiotensin II-induced hypertension is mediated by vascular smooth muscle cell-derived H2O2. Hypertension 46:732–737.
  • Zhu B, Bush D, Doss GA, Vincent S, Franklin RB, Xu S. (2008). Characterization of 1′-hydroxymidazolam glucuronidation in human liver microsomes. Drug Metab Dispos 36:331–338.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.